Molecular Partners AG (MOLN)’in fiyatı nedir?

Molecular Partners AG (MOLN)’in fiyatı $4.43’dir

Molecular Partners AG (MOLN)’in piyasa değeri nedir?

Molecular Partners AG (MOLN)’in piyasa değeri $166.36M’dir.

Molecular Partners AG (MOLN) Fiyat Geçmişi

Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.

Yıl	Performans
2026 (TTM)	-1.97%
2025	-21.29%
2024	23.60%
2023	-35.40%
2022	-60.06%
2021	-31.00%
2020	39.82%
2019	-1.96%
2018	-30.67%
2017	30.64%
2016	-40.17%
2015	0.00%

Yıl

Performans

2026 (TTM)

-1.97%

2025

-21.29%

2024

23.60%

2023

-35.40%

2022

-60.06%

2021

-31.00%

2020

39.82%

2019

-1.96%

2018

-30.67%

2017

30.64%

2016

-40.17%

2015

0.00%

Şirket	Hisse fiyatı	Değişim 1yıl%	Ülke
Vertex Pharmaceuticals Incorporated VRTX.US	$553.09	42.85%	US
Argenx SE ARGX.US	$1.02K	44.02%	NL
Moderna, Inc. MRNA.US	$158.64	541.49%	US
CSL Limited CSL.AX	$121.98	-12.73%	AU
Lonza Group AG LONN.SW	$772.27	7.33%	CH

Şirket

Hisse fiyatı

Değişim 1yıl%

Ülke